Monoclonal Antibodies in Lymphoma
Pp. 256-299 (44)
Esmeralda Chi-yuan Teo and Colin Phipps
Monoclonal antibodies (moAbs) have changed the landscape of lymphoma
therapy. The chimeric anti-CD20 antibody, rituximab was the first to show significant
activity in B-cell lymphomas. Since its FDA approval in 1997, rituximab has become a
standard of care whether in combination with chemotherapy, or as a single-agent in
induction and maintenance regimens in B-cell lymphoma. The success with rituximab
paved the way for a steady stream of anti-lymphoma moAb therapies. Ofatumumab and
obinutuzumab are next generation anti-CD20 antibodies designed to improve the
cytotoxic effect of rituximab and enhance tumor cell killing. The breath of receptors
amenable to Moab targeting extends far beyond CD20 and this chapter will review the
most clinically impactful moAbs that have emerged over the past decade.
Monoclonal antibodies, lymphoma, antibody-drug conjugates,
Department of Haematology, Singapore General Hospital, 20 College Road, Singapore 169856.